Company news
Correvio Pharma Corp news in 2016
Correvio Pharma Corp's news releases, calls and decks from 2016, newest first.
Cardiome Announces Commercial Launch of XYDALBA(TM) (dalbavancin) in Germany
December 20, 2016
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
December 8, 2016
Cardiome Advances Toward the UK XYDALBA(TM) (dalbavancin) Launch
November 29, 2016
Cardiome Reports Third Quarter 2016 Financial Results
November 7, 2016
Cardiome to Reschedule Release of Third Quarter 2016 Financial Results
November 1, 2016
Cardiome to Hold Third Quarter 2016 Financial Results Conference Call on November 7
October 28, 2016
Cardiome Announces Initiation of Commercial Operations in Canada, Eh
October 14, 2016
Cardiome Announces Recent Insider Purchases
August 16, 2016
Cardiome Reports Second Quarter 2016 Financial Results
August 9, 2016
Cardiome Announces XYDALBA(TM) Single Dose Infusion Approval by European Medicines Agency
August 9, 2016
Cardiome Announces the Addition of Two Key Members to its Management Team
August 8, 2016
Cardiome to Hold Second Quarter 2016 Financial Results Conference Call on August 9
August 3, 2016
Cardiome Closes Public Offering of 11,500,000 Common Shares
July 29, 2016
Cardiome Announces Pricing of Public Offering of 10,000,000 Common Shares
July 26, 2016
Cardiome Announces Proposed Public Offering of Common Shares
July 25, 2016
ESMOCARD® and ESMOCARD LYO® receive pricing approval and reimbursement in Italy
July 14, 2016
Cardiome Announces Term Loan Agreement with CRG-Managed Funds
June 14, 2016
Cardiome Reports First Quarter 2016 Financial Results
May 13, 2016
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
May 12, 2016
Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13
May 11, 2016
Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study
May 11, 2016
Cardiome and Allergan Announce XYDALBA(TM) (Dalbavancin) Licensing Agreement in International Markets
May 5, 2016
Cardiome to Present at the Bloom Burton & Co. 5th Annual Healthcare Investor Conference
April 28, 2016
Cardiome Announces Publication of Independent Study Comparing BRINAVESS to Ibutilide in Patients with Recent-Onset Atrial Fibrillation
March 31, 2016
Cardiome Reports Fourth Quarter and Full Year 2015 Financial Results
March 10, 2016
Cardiome Announces Filing of Prospectus Supplements
March 7, 2016
Cardiome To Hold Fourth Quarter And Full Year 2015 Financial Results Conference Call On March 10
March 4, 2016
Cardiome announces filing of shelf prospectus and registration statement
February 19, 2016
Cardiome To Present At The 5th Annual Leerink Partners Global Healthcare Conference
February 10, 2016
Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA
January 27, 2016
Cardiome Announces the Launch of ESMOCARD LYO in Belgium
January 21, 2016
Cardiome announces filing of marketing authorization application for intravenous vernakalant in the Kingdom Of Saudi Arabia
January 13, 2016
Cardiome Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC
January 12, 2016
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency
January 6, 2016
Cardiome Enters Commercialization Agreement with Chong Kun Dang for BRINAVESS® in South Korea
January 5, 2016